<DOC>
	<DOC>NCT01466374</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.</brief_summary>
	<brief_title>Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease</brief_title>
	<detailed_description>Anti-IP10: Anti Interferon-inducible ligand 10</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Adults subjects with confirmed Crohn's Disease (CD) for at least 3 months Moderate to severely active CD as defined by Crohn's Disease Activity Index (CDAI) 220 to 450 In the past have had insufficient response and or intolerance to â‰¥ 1 of the conventional therapy (immunosuppressants, corticosteroids and/or approved biologic therapy) Ulcerative colitis (UC) or indeterminate colitis Short bowel syndrome Known stricture or noninflammatory stenosis leading to symptoms of obstruction Current stoma or current need for colostomy or ileostomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>